A co-formulation of interferons type I and II enhances temozolomide response in glioblastoma with unmethylated MGMT promoter status

Vázquez-Blomquist, Dania; Leenstra, Sieger; Kaaij, Mariëlle van der; Villarreal, Adelaida; Bello-Rivero, Iraldo

doi:10.1007/s11033-020-05604-2

Cited by 2 publications

(1 citation statement)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…169,170 IFNs co-formulation has also been suggested to improve temozolomide therapy by inhibiting the repair enzyme MGMT. 171 Cytokines such as TNF48 and IL2 have also been repurposed, but with limited clinical success due to high toxicity. 172 Investigators have also attempted to repurpose other drugs such as statins, disulfiram, nelfinivir, saracatinib, propranolol, abivertinib, leucovorin, artemisinin, and mibefradil.…”

Section: Drug Repurposing In Oncologymentioning

confidence: 99%

Repurposing: A Potentially Emerging Discipline

Prabhash¹,

Mammen²,

Madhusoodhanan³

et al. 2022

IJPER

View full text Add to dashboard Cite

Drug repurposing is the remodeling of already existing drugs to reduce the time frame, costs, and efforts in developing a new novel drug. This strategy has secured significant momentum in the previous decade. It overcomes the snags and pitfalls in the traditional means of drug discovery. This core research strategy has now become the sole approach to containing many deadly diseases that have no cure in the present. In astound, for pandemics like COVID-19 that is spreading like a wildfire worldwide, large-scale research programs and trials have been carried out to identify and modify existing drugs to counter the novel virus. Thus, this technology of drug repurposing offers a new lease of life, and greatly promotes the progress of the medicine, health, and pharma sectors. The purpose of this study is to understand the current status of drug repurposing in the field of virology, bacteriology, mycology, and oncology for clinical translatability.

show abstract

Section: Drug Repurposing In Oncologymentioning

confidence: 99%

Repurposing: A Potentially Emerging Discipline

Prabhash¹,

Mammen²,

Madhusoodhanan³

et al. 2022

IJPER

View full text Add to dashboard Cite

show abstract

Repurposing approved drugs for cancer therapy

Schein

2021

British Medical Bulletin

View full text Add to dashboard Cite

Background Many drugs approved for other indications can control the growth of tumor cells and limit adverse events (AE). Data sources Literature searches with keywords ‘repurposing and cancer’ books, websites: https://clinicaltrials.gov/, for drug structures: https://pubchem.ncbi.nlm.nih.gov/ Areas of agreement Introducing approved drugs, such as those developed to treat diabetes (Metformin) or inflammation (Thalidomide), identified to have cytostatic activity, can enhance chemotherapy or even replace more cytotoxic drugs. Also, anti-inflammatory compounds, cytokines and inhibitors of proteolysis can be used to control the side effects of chemo- and immuno-therapies or as second-line treatments for tumors resistant to kinase inhibitors (KI). Drugs specifically developed for cancer therapy, such as interferons (IFN), the tyrosine KI abivertinib TKI (tyrosine kinase inhibitor) and interleukin-6 (IL-6) receptor inhibitors, may help control symptoms of Covid-19. Areas of controversy Better knowledge of mechanisms of drug activities is essential for repurposing. Chemotherapies induce ER stress and enhance mutation rates and chromosome alterations, leading to resistance that cannot always be related to mutations in the target gene. Metformin, thalidomide and cytokines (IFN, tumor necrosis factor (TNF), interleukin-2 (IL-2) and others) have pleiomorphic activities, some of which can enhance tumorigenesis. The small and fragile patient pools available for clinical trials can cloud the data on the usefulness of cotreatments. Growing points Better understanding of drug metabolism and mechanisms should aid in repurposing drugs for primary, adjuvant and adjunct treatments. Areas timely for developing research Optimizing drug combinations, reducing cytotoxicity of chemotherapeutics and controlling associated inflammation.

show abstract

A co-formulation of interferons type I and II enhances temozolomide response in glioblastoma with unmethylated MGMT promoter status

Cited by 2 publications

References 40 publications

Repurposing: A Potentially Emerging Discipline

Repurposing: A Potentially Emerging Discipline

Repurposing approved drugs for cancer therapy

Contact Info

Product

Resources

About